Myovant Sciences Ltd. and Pfizer Inc. will launch Myfembree (relugolix/estradiol/norethindrone acetate) in June for heavy menstrual bleeding associated with uterine fibroids after receiving US Food and Drug Administration approval, but the partners will need to overcome some barriers that have limited the commercial success of a similar rival – AbbVie Inc.'s Oriahnn (elagolix/estradiol/norethindrone acetate).
Myovant CEO David Marek and chief medical officer Juan Camilo Arjona Ferreira talked to Scrip on 27 May about how the companies plan to build awareness of the health condition and why the partners are confident patients and physicians who do choose to take one of the two medications will choose Myfembree over Oriahnn
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?